High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease
GastroHep
by Emily Lim, Maxter Thai, Yoon-Kyo An, Peter Hendy, Mahmoud Alchlaihawi, Rupert Leong, Susan Connor, Watson Ng, Bonita Gu, Lena Thin, Miles Sparrow, Robert Gilmore, Kirstin Taylor, Olivia Sallis, Jane M. Andrews, Charlotte Daker, Richard B. Gearry, Gabrielle Wark, Simon Ghaly, Matt Begun, Krupa Krishnaprasad, Tianhong Wu, Leonie Ruddick-Collins, Veronika Schreiber, Satomi Okano, Graham Radford-Smith, Julien Schulberg, Daniel van Langenberg, Jakob Begun, Benjamin Chan
3d ago
Background: Endoscopic balloon dilatation (EBD) is an alternative therapy to avoid or delay surgery in stricturing Crohn’s disease (CD); however, certain factors determining outcomes remain poorly defined, and conflicting evidence exists in current studies. In one of the largest cohorts to date, we assess outcomes following EBD for stricturing CD for both anastomotic and de novo strictures. Methods: A retrospective cohort study of CD patients undergoing EBD was conducted at 12 hospitals across Australia and New Zealand. Local databases were used to identify cases from February 1999 to November ..read more
Visit website
The Suitability of Stool Antigen Testing in the Detection of Helicobacter pylori in a Regional and Rural Area of Australia
GastroHep
by Timothy Wearne, Safaa Nadeem, Bruce Wilson, Kylie J. Mansfield, Caitlin Keighley, Sreedhari Thayalasekaran
3w ago
Background. Helicobacter pylori is considered the most widespread bacterial pathogen worldwide. Successful eradication protocols are well established, highlighting the importance of appropriate infection detection. Noninvasive testing (NIT) methods are commonly used to detect infection, with test selection dependent on access and previous infection. This study examined trends in NIT by age group and test selection for eradication screening as well as examining H. pylori area prevalence by socioeconomic status (SES) in the Illawarra Shoalhaven and surrounding region. Materials and Methods. This ..read more
Visit website
Visualized Quantitative Evaluation of Gastrointestinal Activity in Healthy Volunteers Using a Noninvasive Single‐Channel Electroamplifier
GastroHep
by Gen Aikawa, Misaki Kotani, Hideaki Sakuramoto, Akira Ouchi, Mitsuki Ikeda, Tetsuya Hoshino, Nobuyuki Araki, Yuki Enomoto, Nobutake Shimojo, Yoshiaki Inoue, Sreedhari Thayalasekaran
3w ago
Background. Electrogastrography and electroenterography are noninvasive methods for measuring gastric and intestinal electrical activities, respectively. Few studies have measured electroenterography in healthy humans; however, no studies have measured electrogastrography and electroenterography simultaneously. This study was performed to provide basic electrogastrography and electroenterography data for comparison with future studies in patients. Methods. Simultaneous preprandial and postprandial measurements of electrogastrography and electroenterography were taken for 30 min each in 50 heal ..read more
Visit website
Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single‐Centre, Phase IV Interventional Study with a Nested Qualitative Study
GastroHep
by Clare Harris, Richard James Harris, David Young, Martin McDonnell, Bridget Clancy, Justin Harvey, Carlos Araujo, Ines Iria, Joao Goncalves, Susan Latter, J. R. Fraser Cummings, Arjun Sugumaran
3w ago
Background and Aims. Regulatory pathways compare biosimilars with originator molecules only and not with other biosimilars. With the development of multiple infliximab biosimilars, patients may be asked to transition between them. Data is emerging but there is still a gap in the evidence on switching between infliximab biosimilars. Our aim was to conduct a full evaluation of switching a cohort of IBD patients from one biosimilar (CT-P13) to another (SB2) in a real-world setting including clinical and patient experience and molecular and drug immunogenicity aspects of the process. Methods. Pros ..read more
Visit website
T‐HAD Score: A Novel Diagnostic Model for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease (NAFLD)
GastroHep
by Tharun Tom Oommen, Jijo Varghese, Krishnadas Devadas, Atul Hareendran, Nibin Nahaz, Suprabhat Giri, Than Than Aye
3w ago
Background and Aims. The NAFLD disease spectrum includes simple steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. Progression from NASH, the forerunner of developing cirrhosis, portends a poor outcome as mortality is proportionately increased. This study sought to propose a new diagnostic model for advanced fibrosis in an Asian population cohort affected with NAFLD. Methods. Cross-sectional study conducted in the Department of Medical Gastroenterology, Medical College, Trivandrum. The study period was 2 years. After excluding secondary causes of hepatic steatosi ..read more
Visit website
Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015‐2017: A Real‐Life Study
GastroHep
by Jean-Frédéric Blanc, Caroline Laurendeau, Marie de Zélicourt, Manel Dhaoui, Nadia Kelkouli, Francis Fagnani, Philippe Mathurin, Benjamin Chan
3w ago
Background. The prognosis of patients with hepatocellular carcinoma (HCC) not eligible to curative treatment is poor. Little information is available on treatment modalities and outcomes of these patients in everyday practice. The aim of this analysis was to describe the characteristics of patients with a newly diagnosed intermediate, advanced, or terminal (IAT) stage of HCC (ICD-10: C220) between 2015 and 2017, either present at diagnosis of HCC or having occurred after disease progression; treatment patterns, HCC aetiologies, and the associated survival were determined using the nationwide c ..read more
Visit website
Corrigendum to “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites”
GastroHep
by Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham
3w ago
GastroHep, Volume 2023, Issue 1, 2023 ..read more
Visit website
Primary Hereditary Haemochromatosis and Pregnancy
GastroHep
by Ambrin Gull Shamas, Soe Thiha Maung
3w ago
Background. Haemochromatosis is a rare autosomal genetic disease that can cause multiple organ failure. In the past, this condition was not considered to affect pregnancy. The objectives of this study are to update the management of haemochromatosis in general as there are new treatments being investigated other than phlebotomy and to summarise the effects of the condition on pregnancy and vice versa. Methods. The initial search was in Ovid Medline® from 2002 to 2013. Review articles for haemochromatosis and case reports of its related complications in pregnancy were found. None of the reviews ..read more
Visit website
Spleen Stiffness Measured by 2D‐Shear Wave Elastography and Rebleeding Risk in Cirrhotic Patients Undergoing Endoscopic Variceal Ligation for Variceal Bleeding
GastroHep
by Swetha Sattanathan, Krishnadas Devadas, Shanid Ahmed, Atul Hareendran, Arun Prabhakaran, Nidhin Raveendran, Arjun Sugumaran
3w ago
Background and Aims. Endoscopic variceal ligation (EVL) of esophageal varices alters the portal pressure. We observed the changes in 2D-shear wave elastography (2D-SWE) measurements of spleen and liver following EVL and tried to identify the predictors for rebleeding and mortality at 6 months. Methods. A prospective observational study of 202 patients who underwent EVL for bleeding esophageal varices was done. 2D-SWE measurements of liver stiffness (LS) and spleen stiffness (SS) and spleen volume (SV) were measured half an hour before, 1 hour, 2 weeks, and 6 weeks after EVL. All were followed ..read more
Visit website
Issue Information
GastroHep
by
2y ago
GastroHep, Volume 3, Issue 7, Page 417-419, December 2021 ..read more
Visit website

Follow GastroHep on FeedSpot

Continue with Google
Continue with Apple
OR